Global Multiple Myeloma Therapy Market Overview

Global Multiple Myeloma Therapy Market is estimated to reach USD 31.6 billion by 2030, growing at a CAGR of 5.7% during the forecast period of 2022-2030. It was valued at USD 19.2 billion in 2022.

Multiple myeloma (MM) is a malignant plasma cell disease. Its tumor cells originate from plasma cells in the bone marrow, and plasma cells are cells that develop B lymphocytes to the final functional stage. Therefore, multiple myeloma can be classified as B lymphocytic lymphoma. It is currently classified by WHO as a type of B-cell lymphoma, called plasma cell myeloma/plasmacytoma. It is characterized by abnormal proliferation of bone marrow plasma cells accompanied by an overproduction of monoclonal immunoglobulin or light chain (M protein). Multiple myeloma is characterized by the tumorous proliferation of cloned plasma cells that produce monoclonal immunoglobulins. The disease occurs in the bone marrow and often results in extensive bone destruction with osteolytic lesions, osteopenia, and/or pathological fractures. Other complications associated with the disease also include high calcium hyperlipidemia, renal insufficiency, anemia, and infection.

Global Multiple Myeloma Therapy Market Insights

The growing prevalence of the condition, along with swelling geriatric population across the globe, will propel the globe multiple myeloma therapy market in the upcoming periods. Moreover, the availability of advanced diagnostic techniques such as imaging devices and personalized diagnostic tests would project to boom the global multiple myeloma therapy market in the future timeline. Additionally, the rise in the prevalence of blood cancer and the growing demand for biologic therapies will accelerate the global multiple myeloma therapy industry. Multiple myeloma is sometimes accompanied by multiple osteolytic lesions, hypercalcemia, anemia, and kidney damage.

Furthermore, the surge in the aging population and the rising penetration of novel cancer drugs worldwide will contribute to the growth of multiple myeloma industry in the next few years. In addition, a significant development in technologies and drugs/vaccines for breast cancer, thyroid cancer, and pancreatic cancer which would escalate the global multiple myeloma industry in the forthcoming periods. The emergence of new drugs and the application of autologous hematopoietic stem cell transplantation have significantly improved the prognosis of multiple myeloma.

Growth Driver

The surge in demand for Multiple Myeloma Therapy for cancer and tumor diseases

Although there has been great progress in the treatment of multiple myeloma in recent years, it is still an incurable disease. The purpose of treatment is to prevent or alleviate symptoms and complications, destroy abnormal plasma cells, and slow the progression of the disease. Doctors use different drug combinations based on the characteristics of myeloma and whether the patient is eligible for stem cell transplantation. The drug combination may include thalidomide, lenalidomide, or pomalidomide, and/or bortezomib or carfilzomib, plus glucocorticoids (such as dexamethasone), and/or chemotherapy drugs. Chemotherapy drugs include cyclophosphamide, melphalan, bendamustine, and doxorubicin.

According to WHO, Cancer is a leading cause of death worldwide, accounting for around 9.6 million deaths in 2018. Worldwide, about 1 in 6 deaths is due to cancer.

Product Type Segmental Analysis

Based on product type, the global Multiple Myeloma Therapy market classified into Chemotherapy and Other Drugs (Immunomodulating Agents, Traditional Chemotherapy, Proteasome inhibitors, Histone Deacetylase (HDAC) inhibitors, and Monoclonal Antibodies), Radiation, and Stem Cell Transplant & Other Supportive Treatments. The Chemotherapy and Other Drugs segment predicted to gain a major share in the market by 2030, owing to the unavailability of alternatives and limitations of surgical procedures. It reduces the chances of cancer coming back.

Stem Cell Transplant segment will grow due to new types of procedures and advancements in a stem cell, which reduced-intensity treatment regimen.

End-User Segmental Analysis

Based on end-user, the global Multiple Myeloma Therapy market categorized into Hospitals, Clinics, and Others. Hospitals segment likely to gain maximum revenue by 2030 owing to the surge in demand for multiple myeloma therapy in hospitals with rising incidences of the cancer disease amongst the population.

Clinics segments will drive on account of early check and diagnosis of cancer disease for cancer patients.

Region Segmental Analysis

Based on geography, the global Multiple Myeloma Therapy market size segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America estimated to occupy the lion’s market share by 2030 due to the presence of prominent players in these regions, along with the presence of cancer affected population and the growing adoption of novel therapeutic approaches in the region.

The Asia Pacific will drive attributable to the aging population in these regions, coupled with financial aids by the government for healthcare expenditure.

Competitor Analysis

Companies such as Revlimid, Pomalyst. Janssen Biotech, Inc., Bristol-Myers Squibb Company, Novartis AG, Millennium Pharmaceuticals, Amgen, Inc., Genzyme Corporation, Juno Therapeutics, Celgene Corporation, Johnson and Johnson, AbbVie Inc., Innate Pharma, and Celldex Therapeutics, Inc. are the key players in the Global Multiple Myeloma Therapy Market.

Key Stakeholders

• Market research and consulting firms
• Industry associations
• Global Multiple Myeloma Therapy providers
• Research organizations and consulting companies
• Organizations, associations, and alliances related to multiple myeloma therapy
• Regulatory bodies

Scope of the report

Recent Developments

1. In September 2021, Apotex Inc. launched the generic version of Revlimid capsules, APO-lenalidomide, to treat multiple myeloma and Myelodysplastic syndrome.
2. In August 2021, Pfizer announced to acquire Trillium Therapeutics Inc.
3. In August 2021, Senhwa Biosciences announced dose-escalation initiation of the phase I trial of pidnarulex to treat Advanced Hematological Malignancies.

The objective of the Research

• Market modeling starts with identifying a target market where historical data exists. A Market can include prediction problems, economic factors, analyzing customer behavior, and identifying new patterns from past events, which helps our client to have deep dive into the market.
• Product analysis involves steps such as examining product features, costs, availability, quality, and other aspects. Product analysis is conducted to understand potential buyers and measure competition in the market.
• Market Trend and Economic Factors Analysis helps in assessing potential changes to an economy’s inflation rate, taxes, interest rates, exchange rates, trading regulations, and excise duties that can or have a major effect on the target market.
• Market Segmental Analysis defines in-depth scenario of the target market by the process of grouping consumers into naturally existing created segments of consumers who share similar product preferences or characteristics
• The geographical mapping approach helps our clients to understand national or international markets because different consumers in different regions have different needs wants, and cultural characteristics that can be specifically targeted.

Market Modelling

By Therapy Type

• Chemotherapy and Other Drugs
  • Traditional Chemotherapy
  • Immunomodulating Agents
  • Proteasome inhibitors
  • Histone Deacetylase (HDAC) inhibitors
  • Monoclonal Antibodies)
• Radiation
• Stem Cell Transplant & Other Supportive Treatments

By End-User

• Hospitals
• Clinics
• Others

By Region

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Video Telemedicine Market

AI in Telehealth and Telemedicine Market

Synthetic Leather Market

Automotive 48V System Market

Zinc Oxide Market

Paints and Coating Market

EV Infrastructure Market

Peripheral Vascular Devices Market

Emerging Therapies

Report Content

1.     Research Strategic Development

1.1. Market Modelling

1.2. Product Analysis

1.3. Market Trend and Economic Factors Analysis

1.4. Market Segmental Analysis

1.5. Geographical Mapping

1.6. Country Wise Segregation

2.     Research Methodology

2.1. Identification of Target Market

2.2. Data Acquisition

2.3. Refining of Data/ Data Transformations

2.4. Data Validation through Primary Techniques

2.5. Exploratory Data Analysis

2.6. Graphical Techniques/Analysis

2.7. Quantitative Techniques/Analysis

2.8. Visual Result/Presentation

3.     Executive Summary
4.     Market Insights

4.1. Supply Chain Analysis

4.2. Economic Factor Analysis

4.2.1. Drivers

4.2.2. Trends

4.2.3. Opportunities

4.2.4. Challenges

4.3. Technological Landscape

4.4. Competitors & Product Analysis

4.5. Regulatory Framework

4.6. Company market share analysis, 2022

4.7. Porter’s Five forces analysis

4.8. Price point analysis

4.9. New Investment Analysis

4.10.            PESTEL Analysis

5.     Global Multiple Myeloma Therapy Market Overview

5.1. Market Size & Forecast,2017-2030

5.1.1. Demand

5.1.1.1. By Value (USD Billion)

5.2. Market Share & Forecast, 2017-2030

5.2.1.     By Therapy Type

5.2.1.1.            Chemotherapy and Other Drugs

5.2.1.1.1.               Traditional Chemotherapy

5.2.1.1.2.               Immunomodulating Agents

5.2.1.1.3.               Proteasome inhibitors

5.2.1.1.4.               Histone Deacetylase (HDAC) inhibitors

5.2.1.1.5.               Monoclonal Antibodies

5.2.1.2.            Radiation

5.2.1.3.            Stem Cell Transplant & Other Supportive Treatment

5.2.2.     By End-User

5.2.2.1.            Hospitals

5.2.2.2.            Clinics

5.2.2.3.            Others

5.2.3.     By Region

5.2.3.1.            North America

5.2.3.2.            Europe

5.2.3.3.            Asia-Pacific

5.2.3.4.            South America

5.2.3.5.            The Middle East & Africa

6.     North America Multiple Myeloma Therapy Market Overview

6.1. North America Multiple Myeloma Therapy Market Size & Forecast,2017-2030

6.1.1. Demand

6.1.1.1. By Value (USD Billion)

6.2. Market Share & Forecast, 2017-2030

6.2.1. By Therapy Type

6.2.1.1.            Chemotherapy and Other Drugs

6.2.1.1.1.               Traditional Chemotherapy

6.2.1.1.2.               Immunomodulating Agents

6.2.1.1.3.               Proteasome inhibitors

6.2.1.1.4.               Histone Deacetylase (HDAC) inhibitors

6.2.1.1.5.               Monoclonal Antibodies

6.2.1.2.            Radiation

6.2.1.3.            Stem Cell Transplant & Other Supportive Treatment

6.2.2. By End-User

6.2.2.1.            Hospitals

6.2.2.2.            Clinics

6.2.2.3.            Others

6.2.3. By Country

6.2.3.1.            US

6.2.3.2.            Canada

6.2.3.3.            Mexico

6.2.4. Company Market Share (Top 3-5)

6.2.5. Economic Impact Study on North America Multiple Myeloma Therapy Market

7.     Europe Multiple Myeloma Therapy Market Overview

7.1. Europe Multiple Myeloma Therapy Market Size & Forecast,2017-2030

7.1.1. Demand

7.1.1.1. By Value (USD Billion)

7.2. Market Share & Forecast, 2017-2030

7.2.1. By Therapy Type

7.2.1.1.            Chemotherapy and Other Drugs

7.2.1.1.1.               Traditional Chemotherapy

7.2.1.1.2.               Immunomodulating Agents

7.2.1.1.3.               Proteasome inhibitors

7.2.1.1.4.               Histone Deacetylase (HDAC) inhibitors

7.2.1.1.5.               Monoclonal Antibodies

7.2.1.2.            Radiation

7.2.1.3.            Stem Cell Transplant & Other Supportive Treatment

7.2.2. By End-User

7.2.2.1.            Hospitals

7.2.2.2.            Clinics

7.2.2.3.            Others

7.2.3. By Country

7.2.3.1.            Germany

7.2.3.2.            UK

7.2.3.3.            France

7.2.3.4.            Italy

7.2.3.5.            Rest of Europe

7.2.4.      Company Market Share (Top 3-5)

7.2.5.      Economic Impact Study on Europe Multiple Myeloma Therapy Market

8.     Asia-Pacific Multiple Myeloma Therapy Market Overview

8.1. Asia-Pacific Multiple Myeloma Therapy Market Size & Forecast,2017-2030

8.1.1. Demand

8.1.1.1. By Value (USD Billion)

8.2. Market Share & Forecast, 2017-2030

8.2.1. By Therapy Type

8.2.1.1.            Chemotherapy and Other Drugs

8.2.1.1.1.               Traditional Chemotherapy

8.2.1.1.2.               Immunomodulating Agents

8.2.1.1.3.               Proteasome inhibitors

8.2.1.1.4.               Histone Deacetylase (HDAC) inhibitors

8.2.1.1.5.               Monoclonal Antibodies

8.2.1.2.            Radiation

8.2.1.3.            Stem Cell Transplant & Other Supportive Treatment

8.2.2. By End-User

8.2.2.1.            Hospitals

8.2.2.2.            Clinics

8.2.2.3.            Others

8.2.3. By Country

8.2.3.1.            India

8.2.3.2.            Japan

8.2.3.3.            Australia

8.2.3.4.            Rest of Asia Pacific

8.2.4.      Company Market Share (Top 3-5)

8.2.5.      Economic Impact Study on Asia Pacific Multiple Myeloma Therapy Market

9.     South America Multiple Myeloma Therapy Market Overview

9.1. South America Multiple Myeloma Therapy Market Size & Forecast,2017-2030

9.1.1. Demand

9.1.1.1. By Value (USD Billion)

9.2. Market Share & Forecast, 2017-2030

9.2.1. By Therapy Type

9.2.1.1.            Chemotherapy and Other Drugs

9.2.1.1.1.               Traditional Chemotherapy

9.2.1.1.2.               Immunomodulating Agents

9.2.1.1.3.               Proteasome inhibitors

9.2.1.1.4.               Histone Deacetylase (HDAC) inhibitors

9.2.1.1.5.               Monoclonal Antibodies

9.2.1.2.            Radiation

9.2.1.3.            Stem Cell Transplant & Other Supportive Treatment

9.2.2. By End-User

9.2.2.1.            Hospitals

9.2.2.2.            Clinics

9.2.2.3.            Others

9.2.3. By Country

9.2.3.1.            Brazil

9.2.3.2.            Argentina

9.2.3.3.            Rest of South America

9.2.4.      Company Market Share (Top 3-5)

9.2.5.      Economic Impact Study on South America Multiple Myeloma Therapy Market

10. The Middle East & Africa Multiple Myeloma Therapy Market Overview

10.1.            The Middle East & Africa Multiple Myeloma Therapy Market Size & Forecast,2017-2030

10.1.1.                        Demand

10.1.1.1.        By Value (USD Billion)

10.2.            Market Share & Forecast, 2017-2030

10.2.1.                        By Therapy Type

10.2.1.1.        Chemotherapy and Other Drugs

10.2.1.1.1.           Traditional Chemotherapy

10.2.1.1.2.           Immunomodulating Agents

10.2.1.1.3.           Proteasome inhibitors

10.2.1.1.4.           Histone Deacetylase (HDAC) inhibitors

10.2.1.1.5.           Monoclonal Antibodies

10.2.1.2.        Radiation

10.2.1.3.        Stem Cell Transplant & Other Supportive Treatment

10.2.2.                        By End-User

10.2.2.1.        Hospitals

10.2.2.2.        Clinics

10.2.2.3.        Others

10.2.3.                        By Country

10.2.3.1.  Saudi Arabia

10.2.3.2.  UAE

10.2.3.3.  South Africa

10.2.3.4.  Rest of the Middle East & Africa

10.2.4.                    Company Market Share (Top 3-5)

10.2.5.                    Economic Impact Study on Middle East & Africa Multiple Myeloma Therapy Market

11. Competitor Analysis

11.1.   Company Description

11.2.   Financial Analysis

11.3.   Key Products

11.4.   Key Management Personnel

11.5.   Contact Address

11.6.   SWOT Analysis

11.7.   Company Profile

11.7.1. AbbVie, Inc.

11.7.2. Revlimid

11.7.3. Pomalyst

11.7.4. Janssen Biotech, Inc.

11.7.5. Bristol-Myers Squibb Company

11.7.6. Novartis AG

11.7.7. Millennium Pharmaceuticals

11.7.8. Amgen, Inc.

11.7.9. Genzyme Corporation

11.7.10.                        Juno Therapeutics

11.7.11.                        Celgene Corporation

11.7.12.                        Johnson and Johnson

11.7.13.                        Innate Pharma

11.7.14.                        Other Prominent Players